Xinhua Pharmaceutical subsidiary gains China approval for Alzheimer’s drug Donepezil tablets
On September 20, Xinhua Pharmaceutical’s wholly-owned subsidiary, Zibo Xinda Pharmaceutical, received a Drug Registration Certificate from China’s National Medical Products Administration for Donepezil Hydrochloride Orally Disintegrating Tablets, used to treat mild to severe Alzheimer’s disease. The drug is covered under China’s national medical insurance as a Category B item. Sales of donepezil formulations in Chinese public medical institutions reached approximately 620 million yuan in 2025.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Xinhua Pharmaceutical Subsidiary Gets Drug Certificate for Alzheimer's Treatment
Xinhua Pharmaceutical (000756) announced on September 20 via a company disclosure that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Donepezil Hydrochloride Orally Disintegrating Tablets from China's National Medical Products Administration. The product, with a specification of 5mg and registration category Chemical Drug Class 4, is indicated for treating mild, moderate, or severe symptoms of Alzheimer's disease. It is listed as a Category B item in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2025 Edition). According to relevant statistical data cited in the report, sales of donepezil formulations in China's public medical institutions amounted to approximately RMB 620 million in 2025.
Read sourceXinhua Pharmaceutical Subsidiary Gets Drug Certificate for Alzheimer's Treatment
Xinhua Pharmaceutical (000756) announced on September 20 that its wholly-owned subsidiary, Xinda Pharmaceutical, has received the Drug Registration Certificate for Donepezil Hydrochloride Orally Disintegrating Tablets from China's National Medical Products Administration. The drug is indicated for the treatment of mild, moderate, or severe symptoms of Alzheimer's disease. It is classified as a Category B item under China's national medical insurance scheme, which typically provides partial reimbursement. The announcement was made via a filing and reported by National Business Daily.
Read sourceXinhua Pharmaceutical Subsidiary Gets Drug Certificate for Alzheimer's Treatment
Xinhua Pharmaceutical (000756.SZ) announced on September 20 that its wholly-owned subsidiary, Xinda Pharmaceutical, has received a 'Drug Registration Certificate' from China's National Medical Products Administration for Donepezil Hydrochloride Orally Disintegrating Tablets. The drug is indicated for the treatment of mild, moderate, or severe symptoms of Alzheimer's disease and is classified as a Category B item under China's medical insurance scheme. According to the announcement, sales of donepezil formulations in Chinese public medical institutions reached approximately RMB 620 million in 2025. The company stated that this approval helps enrich its product portfolio in the central nervous system field and enhances its overall competitiveness.
Read sourceShow 5 older updatesHide older updates
Xinhua Pharmaceutical Subsidiary Gets Drug Certificate for Donepezil Tablets
On the evening of September 20, Xinhua Pharmaceutical announced that its subsidiary has received a Drug Registration Certificate for Donepezil Hydrochloride Orally Disintegrating Tablets. The product is listed as a Category B item in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 Edition). According to relevant statistical data cited in the report, sales of donepezil formulations in China's public medical institutions reached approximately RMB 620 million in 2025. The announcement was sourced from Beijing Business Today and reported via East Money's company news section.
Read sourceXinhua Pharmaceutical Receives Drug Registration Certificates for Three Products
On September 20, Xinhua Pharmaceutical announced that it has obtained drug registration certificates for three products from Chinese regulatory authorities. Levocarnitine Oral Solution is indicated for the treatment of primary systemic carnitine deficiency. Magnesium Sulfate, Sodium Sulfate, and Potassium Sulfate Concentrated Oral Solution is intended for adults and used for bowel cleansing prior to any procedure requiring bowel preparation. Donepezil Hydrochloride Orally Disintegrating Tablets are indicated for the treatment of mild, moderate, or severe symptoms of Alzheimer's disease. The announcement was sourced from the Securities Times Network and reported by East Money, a Chinese financial news platform.
Read sourceXinhua Pharmaceutical Gets Drug Registration Certificates for Levocarnitine and Other Products
Xinhua Pharmaceutical (000756) announced on September 20 that it has received drug registration certificates from China's National Medical Products Administration (NMPA) for Levocarnitine Oral Solution and Magnesium Sulfate, Sodium and Potassium Concentrated Solution for Oral Use. Additionally, its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., obtained a certificate for Donepezil Hydrochloride Orally Disintegrating Tablets. Levocarnitine Oral Solution is indicated for primary systemic carnitine deficiency. The magnesium sulfate solution is used for bowel cleansing before procedures requiring bowel preparation. Donepezil Hydrochloride Orally Disintegrating Tablets are for treating mild, moderate, or severe symptoms of Alzheimer's disease. The announcement was made via a stock exchange filing and reported by People's Finance News.
Read sourceXinhua Pharma Subsidiary Gets Donepezil Hydrochloride Orally Disintegrating Tablet Certificate
On September 20, Shandong Xinhua Pharmaceutical Company Limited (stock code: 000756.SZ) announced that its wholly-owned subsidiary, Zibo Xinda Pharmaceutical Co., Ltd., has received a Drug Registration Certificate from the National Medical Products Administration for Donepezil Hydrochloride Orally Disintegrating Tablets. The product is indicated for the treatment of mild, moderate, or severe Alzheimer's disease symptoms. This regulatory approval allows the subsidiary to manufacture and market the drug in China, expanding its product portfolio in the central nervous system therapeutic area.
Read sourceXinhua Pharmaceutical Subsidiary Obtains Registration Certificate for Donepezil Orally Disintegrating Tablets
On September 20, Xinhua Pharmaceutical's subsidiary received a registration certificate for Donepezil Hydrochloride Orally Disintegrating Tablets, a prescription drug classified as Chemical Drug Category 4. The drug is indicated for the treatment of mild, moderate, or severe Alzheimer's disease symptoms. According to statistics, sales of donepezil formulations in Chinese public medical institutions in 2025 are estimated at approximately 620 million yuan. The successful registration is expected to enrich the company's product portfolio in the central nervous system field and enhance its overall competitiveness. In mid-2026, Xinhua Pharmaceutical reported revenue of 4.358 billion yuan and net profit attributable to shareholders of 149 million yuan. The article was sourced from Caizhongshe.